Assessing and Enhancing Blood Pressure Control Protocols

Adults at high risk for cardiovascular disease who receive intensive systolic blood pressure control have significantly lower rates of death and cardiovascular disease events than those who receive standard control. However, the lifetime health benefits and health care costs associated with intensive control are not known. Continue reading → Assessing and Enhancing Blood Pressure Control Protocols

Research Statement

I am a cardiovascular clinical pharmacist with training in epidemiology and pharmacogenetics. We focus on disparities in prevention and treatment of cardiovascular disease with a focus on hypertension and antihypertensive medication use. Using pharmacoepidemiology and pharmacogenetics, we try to better understand causes of racial differences in medication responses and outcomes. We apply these findings to understand the population-level impact, generalizability, and cost-effectiveness in diverse groups.